| Trial ID: | L5971 |
| Source ID: | NCT01984606
|
| Associated Drug: |
Empagliflozin
|
| Title: |
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Empagliflozin|DRUG: Placebo|DRUG: Sitagliptin|DRUG: Placebo
|
| Outcome Measures: |
Primary: The change from baseline in HbA1c after 52 weeks of treatment., Baseline and week 52 | Secondary: The change in bodyweight (kg) from baseline after 52 weeks of treatment, Baseline and week 52|The change in Systolic Blood Pressure (SBP) from baseline after 52 weeks of treatment, Baseline and week 52|The coefficient of durability of HbA1c response between 24 weeks and 52 weeks of treatment, Week 24 and week 52|The change in Diastolic Blood Pressure (DBP) from baseline after 52 weeks of treatment, Baseline and week 52
|
| Sponsor/Collaborators: |
Sponsor: Boehringer Ingelheim | Collaborators: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2015-01
|
| Completion Date: |
2017-02
|
| Results First Posted: |
|
| Last Update Posted: |
2014-10-27
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01984606
|
